1. Introduction {#sec1}
===============

Zoonotic food- and waterborne pathogens began resistant to antibiotics. It is now evident that antimicrobial resistance is an environmental problem. Detectable antibiotic residues are present in waste water from water treatment plants \[[@B1]\], and antibiotic-resistant bacteria can be isolated from ground water and soil \[[@B2], [@B3]\]. The cause of contamination may be*inter alia* the consequence of farming practices. Use of antibiotics, as growth promoters or for prophylaxis in farm animals, selects resistant strains of enterobacteria in gastrointestinal tract. These resistant strains have been also isolated from food and consequently this represents the main way to spread in the human gastrointestinal tract \[[@B4], [@B5]\]. The increasing incidence of foodborne diseases, coupled with the resultant social and economic implications, causes a constant striving to produce safer feed and food, as to develop new natural antimicrobial agents \[[@B6]--[@B8]\].

Meat contamination by pathogen bacteria may have great health consequence and high impact on consumers. The most known cases are related to HUS, hemolytic uremic syndrome, that was first recognized in 1982 in USA and Canada, with outbreaks associated with fast food restaurants. People experienced gastroenteritis with bloody diarrhoea, caused by the lining of their microbiota. In 1993, a multistate outbreak generated international interest in this disease, popularized by the name "hamburger disease." Hamburger disease is based on association with the consumption of ground beef patties containing a pathogen*Escherichia coli*. This should not be confused with the related benign*E. coli* that is in the gut of every mammal. Many strains of*E. coli*are part of the nonpathogenic facultative flora of intestinal tract of humans and other mammals. However, some of them induce diseases of the gastrointestinal and urinary tracts or may affect the central nervous system \[[@B9]\].

On the basis of their pathogenetic mechanism, diarrheagenic*E. coli* strains include ETEC (enterotoxigenic*E. coli*), EIEC (enteroinvasive*E. coli*), EHEC (enterohemorrhagic*E. coli*), EPEC (enteropathogenic*E. coli*), EAEC (enteroaggregative*E. coli*), and DAEC (diffusely adherent*E. coli*). All of them cause serious economic losses in farm animal herds and are widespread in newborns \[[@B10]\] in developed and developing countries. There is a wide range of transmission possibilities of these pathogens, including direct contact, food, drinks, environment, and others \[[@B11]\]. Epidemiology and clinical symptoms of the disease are similar in various animal species but the majority of strains are species-specific. They differ particularly in the type of the expressed surface "adherence" antigen (adhesin or pilus). These microorganisms produce two main types of virulence factors, that is, adhesins and enterotoxins.

In this work, a collection of*E. coli* isolates was considered. They were different in geographical origin and source of isolation and showed different pathogenetic characteristics.

Consumers look for meat products of upgraded sensory quality and increased functional and nutritional properties, as well as guaranteed safety but yet less processing, and fewer additives or "technological" interventions. Plant derived extracts, or phytocomplex, as effective antimicrobial agents, offer an alternative to synthetic food additives.

Neem (*Azadirachta indica* A. Juss) is considered one of the most promising trees of the 21st century, for its great potential in pest management, environment protection, and medicine \[[@B12]\]. Neem oil (NO) is the most important derived product with a great market worldwide. It contains about one hundred biologically active compounds. The most famous constituents are several nortriterpenes, named limonoids, that is, azadirachtin, nimbin, nimbidin, and nimbolide, besides the predominant oily constituents. NO is the most commercially relevant product obtained from the seeds. The neem cake is remaining after the extraction process.

In our previous studies, the antibacterial activity of NO against*E. coli*was investigated \[[@B13], [@B14]\]. The antibacterial activity resulted highest in comparison to the neem cake extract against meat spoilage microorganisms. The aim of the present work was to evaluate NO capability to cope with plastic genome of*E. coli*.

2. Materials and Methods {#sec2}
========================

2.1. Bacterial Strains and Growth Conditions {#sec2.1}
--------------------------------------------

Forty-eight strains of*E. coli* were considered. Among them, seventeen (FLC isolates) were from microorganism\'s collection of the Fodder and Dairy Productions Research Centre of Lodi (CRA FLC) of CRA. They were isolated from milk and cheese. All strains were typed both phenotypically and genotypically. Phenotyping was made by the PhenePlate system for*E. coli* (PhP-EC, PhPPlate Microplate Techniques AB, Stockholm, Sweden) and genetic characterization by RAPD PCR technique \[[@B15]\].

Seventeen CVVI isolates were from microorganism\'s collection of the Institute of Veterinary Research and Development of Central Vietnam, Vietnam. These microorganisms were isolated from faeces of calves affected by diarrhoea.

Ten NL isolates were from microorganism\'s collection of the Department of Bacteriology of Wageningen UR Livestock Research, Wageningen University & Research Centre, Netherlands. They were isolated from faeces of piglets and calves. They are antigenically different and detectable using specific monoclonal antibodies towards different fimbria antigens by*in vitro* agglutination test \[[@B16]\]. Four reference strains were also considered (DSMZ and ATCC isolates). They were from international culture collections.

The cultivation/assay medium for*E. coli* was Minca + 1% Iso Vitalex Agar/Broth (Sifin, Berlin, Germany). Bacterial cultures for antibacterial testing were prepared by picking colony from 24-hour-old plates and suspending them in the broth medium (5 mL). Cultures were grown aerobically for 18 h at 37°C and 100 rpm. For antibacterial activity assay, 1 mL of each culture was diluted to 10^5^--10^6^ CFU/mL. The reference strains were grown on media and at the growth conditions as reported on products sheets.

2.2. Plant Extract {#sec2.2}
------------------

A commercial neem oil produced by Neem Italia (Manerba (BS), Italy) was used as test starting material (0.35% azadirachtin A). Total composition of the neem oil was checked by high performance thin layer chromatography \[[@B17]\].

Neem oil was diluted in Tween 80 (1 : 1 V/V; VWR, PBI International, MI, Italy) under agitation and sterilised by filtration through a 0.22 *μ*m Millipore express filter (Millex-GP, Bedford, OH, USA) before use in the experiment.

2.3. HPTLC Assay {#sec2.3}
----------------

### 2.3.1. HPTLC System and Materials {#sec2.3.1}

The HPTLC system (CAMAG, Muttenz, Switzerland) consisted of (i) Linomat 5 sample applicator using 100 *μ*L syringes, connected to a nitrogen tank; (ii) ADC 2 chamber containing twin trough chamber 20 × 10 cm; (iii) immersion device III; (iv) TLC Plate Heater III; (v) TLC visualizer; (vi) TLC scanner 3 linked to winCATS software.

Solvents for extraction and HPLC grade solvents were purchased from Sigma-Aldrich and Carlo Erba (Milan, Italy). Glass plates 20 cm × 10 cm with glass-backed layers silica gel 60 (2 *μ*m thickness) were from Merck (Darmstadt, Germany). Before use, plates were prewashed with methanol and dried for 3 min at 100°C. Standards used in the HPTLC analysis were isolated from neem cake (i.e., salannin, azadirachtin A, and unsaturated and saturated lipids) in previous research \[[@B18]\] and data concerning isolation and identification are not reported, but they are available per request. Limonoids standards concentration was 2 mM.

2.4. Sample Application {#sec2.4}
-----------------------

Filtered solutions were applied with nitrogen flow. Operating conditions were syringe delivery speed, 10 s *μ*L^−1^ (100 nL s^−1^); injection volume, 2 *μ*L; band width, 6 mm; distance from bottom, 15 mm.

2.5. Development {#sec2.5}
----------------

The HPTLC plates were developed in toluene : AcOEt 7 : 3 (v/v) as mobile phase ([Figure 1](#fig1){ref-type="fig"}), in the automatic and reproducibly developing chamber ADC 2, saturated with the same mobile phase for 20 min at room temperature. The developing solvents (i.e., type of solvents and ratios) were carefully optimized before the analyses. The length of the chromatogram run was 80 mm from the point of application. The developed layers were allowed to dry in air for 5 min, derivatized with a selected solution, including *p*-anisaldheyde (1.5 mL *p*-anisaldheyde, 2.5 mL H~2~SO~4~, and 1 mL AcOH in 37 mL EtOH), dried in the open air, and then dipped into Macrogol reagent (1 g polyethylene glycol 400 in 20 mL of dichloromethane). Finally, the plates were warmed for 5 min at 120°C before inspection. All treated plates were inspected by a CAMAG TLC visualizer under a UV light at 254 or 366 nm or under reflectance and transmission white light (WRT), respectively, before and after derivatization.

2.6. Molecular Biology Characterization of the*E. coli* Isolates {#sec2.6}
----------------------------------------------------------------

Two primer pairs that amplify specific*E. coli* 16S rRNA sequences and fourteen primer pairs that specifically amplify target gene coding for virulence factors (adhesins and toxins) were employed to characterize the*E. coli* isolates considered in this study ([Table 1](#tab1){ref-type="table"}). The PCR reaction mixtures and conditions are those as reported in the literature ([Table 1](#tab1){ref-type="table"}).

The amplification products\' sizes, coordinates, and accession numbers of each primer pair are shown in [Table 2](#tab2){ref-type="table"}. Amplified products (7 *μ*L) were analyzed by electrophoresis in 2% or 3% agarose gels buffered in 0.5x TBE (TBE buffer: 90 mM tris(hydroxymethyl)aminomethane, 90 mM boric acid, and 3 mM ethylenediaminetetraacetate Na salt, pH 8.3, Sigma-Aldrich, Milano, Italy) against a 50 bp, 100 bp, and 1 Kb ladder used as size marker (Invitrogen, Milano, Italia) and visualized by UV light at 260 nm (Fotodine 3-3102 Celbio, Milano, Italy) after staining with ethidium bromide (3,8-diamino-5-ethyl-6-phenylphenanthridinium bromide, EtBr, Sigma-Aldrich, Milano, Italy).

2.7. Assessment of Antibacterial Activity {#sec2.7}
-----------------------------------------

The antibacterial activity of the NO was assayed using standardized disc diffusion agar and microdilution methods. Disc diffusion method was carried out according to the standard method by Bauer et al. \[[@B19]\]. Bacteria cultures adjusted to 0.5 McFarland standard were used to lawn Muller Hinton agar plates evenly using a sterile swab. The agar plates were dried for 15 minutes. The discs impregnated with NO (100 *μ*L) were placed on the agar surface. Each test plate comprises three discs. The discs were placed equidistant to each other. Muller Hinton agar plates were set also up with positive control, which is the antibiotic ciprofloxacin (CFX) (100 *μ*L wt/v) (hydrochloride monohydrate 1 mg/mL, Bayer, Milano, Italy) and Tween 80 (TWN) (VWR International PBI Srl, Milano, Italy, 1 mg/mL) as negative control. The plates were then incubated at 37°C for 18 h. After the incubation, the plates and those considered as controls were examined for inhibition zone. The inhibition zones were then measured using calipers and were recorded. The plates were done in triplicate for each bacterial isolate and the experiment was performed twice. The results were recorded as mean ± S.D. of the duplicate experiment. Differences between means of data were compared by LSD calculated using the SAS.

The antibacterial activity of NO was also evaluated using microdilution method in conventional sterile polystyrene microplates (Corning, Euroclone SpA, Milan, Italy). Each well of the microplate was filled with 100 *μ*L of sterile suitable liquid media for each bacterial isolate considered, 50 *μ*L of inoculums and amounts of extract at lower concentrations (1 : 10--1 : 10,000) were added. Control treatment without NO was used in the experiment. The microplates were incubated at 37°C for 24 h. Bacterial growth was determined by OD reading at 630 nm/10 mm pathlength with an ELISA microplate reader (Dynatech ML-3000, Pina de Ebro, Spain). Bacterial cell concentration was transformed to cells/mL using the reference curve equation.

The reference curve was constructed by diluting at 1 : 100 each bacterial isolate. Counting the number of bacterial cells of an aliquot of this dilution was done using a Neubauer chamber (Celeromics, Vedano al Lambro, MI, Italy). Finally, cell concentrations were transformed to a percentage of bacterial inhibition. The percentage of bacterial growth reduction (GR%) was estimated using as reference the control treatment (*T* = without extract) as$$\begin{matrix}
{\text{GR}\% = \frac{C - T}{C} \times 100.} \\
\end{matrix}$$

Three replicates were considered. The results were recorded as mean ± S.D. of the duplicate experiment. Differences between means of data were compared by least significant difference (LSD) calculated using the SAS.

3. Results and Discussion {#sec3}
=========================

3.1. Molecular Biology Characterization of the*E. coli* Isolates {#sec3.1}
----------------------------------------------------------------

The molecular biology characterization of the forty-eight*E. coli* isolates showed that fourteen isolates were diarrheagenic*E. coli*. They were ten*E. coli* isolated from feces of calves and piglets and four from calves collected, respectively, in Netherlands and Central Vietnam. Their virulence characteristics are reported in [Table 3](#tab3){ref-type="table"}.

3.2. HPTLC Assay {#sec3.2}
----------------

The NO metabolomic fingerprint shows characteristic sequence of metabolites according to the polarity of constituents. The identification of the raw material was assured by the presence of salannin (Rf = 0.42), which is a typical maker of neem. In comparison with the spot of azadirachtin (Rf = 0.23), salannin appears as the main limonoid spot. Spots concerning lipids are present at Rf values at ca. 0.80, due to unsaturated fatty acids and fatty alcohols, and at Rf ca. 0.50, due to saturated and unsaturated triglycerides. The most interesting feature of the plate concerns the presence of compounds with high fluorescent reaction at between Rf 0.55 and 0.66, which are perfectly visible at 366 nm after derivatization with *p*-anisaldheyde. These spots can be attributed to compounds with high conjugated unsaturation in polycyclic aromatic structures, very different from those of the nortriterpenes limonoids, so far considered responsible for the activity. Therefore, more studies are necessary to decide about the importance of antibacterial activity of these substances in the phytocomplex.

3.3. NO Antibacterial Activity {#sec3.3}
------------------------------

The results obtained show that NO has a broad spectrum of antibacterial activities against the tested*E. coli* isolates. As shown in [Table 4](#tab4){ref-type="table"}, the antibacterial activity was evaluated based on the diameters of clear inhibition zone surrounding the paper discs soaked with 100 *μ*L of neem oil. The NO average GIZ mm range from 9.50 ± 0.70 to 30.00 ± 1.00. The NO GIZ varies between enteropathogenic and nonenteropathogenic*E. coli* being, respectively, 24.33 ± 0.58--30.00 ± 1.00 and 9.50 ± 0.70--21.53 ± 1.53. It is significantly (*P* \< 0.05) different with respect to the antibiotic activity. However, the*E. coli* isolate FLC1167 (from milk) resulted to be less susceptible and the*E. coli* isolate NLP097/F5 (from piglet feces) the most susceptible to NO treatment (100 *μ*L) among all tested bacteria using the disc diffusion method.

The CFX GIZ range is 0.00 ± 0.00--32.65 ± 75. The enteropathogenic*E. coli* resulted to be resistant or less susceptible to CFX than the nonenteropathogenic*E. coli*, showing a GIZ range of, respectively, 0.00 ± 0.00--18.24 ± 1.68 mm and 21.64 ± 0.94--32.65 ± 75 mm. The isolates CVVIK10B (from calve feces) and NLK99-3^\*^ (from calve feces) both revealed resistance to CFX. No GIZ was detected in plates treated with negative controls (TWN and WTR).

As shown in [Table 5](#tab5){ref-type="table"}, the percent bacterial GR revealed at 100 *μ*L, 10 *μ*L, 1 *μ*L, and 0.1 *μ*L NO concentrations was in the range 23.71 ± 1.00--99.70 ± 1.53; 21.61 ± 0.56--91.63 ± 0.08; 17.58 ± 1.33--69.57 ± 0.00; and 11.18 ± 0.89--67.58 ± 0.89.

There is a significant difference of antibacterial activity among the isolates and the NO concentrations tested ([Table 5](#tab5){ref-type="table"}). The highest percent bacterial GRs were detected at 100 *μ*L NO and they concerned mainly enteropathogenic*E. coli* isolates. Amplicons of the expected sizes from virulence genes of enteropathogenic*E. coli* isolates were not detected when bacterial viable cells were checked in samples treated with 100 *μ*L and 10 *μ*L NO concentrations. On the contrary, amplicons of the expected size were revealed in the same samples using primer pair numbers 16 and 17, as reported in [Table 1](#tab1){ref-type="table"}, that specifically amplify unique sequences of*E. coli* 16S rRNA.

The antibiotic activity of ciprofloxacin is to bind and inhibit bacterial topoisomerase types II and IV, thus being able to interfere with the bacterial processes of replication, transcription, and DNA repair.

An increasing ciprofloxacin resistance of*E. coli* isolates was reported \[[@B20]\] according several epidemiological studies.*E. coli*, the most commonly isolated bacterium in clinical samples from patients affected by different severity of diarrheal symptoms, shows high antibiotic resistance \[[@B21], [@B22]\]. Diarrheagenic*E. coli*, considered in the experiment, showed a resistance or less susceptibility to ciprofloxacin, in comparison with the other nonenteropathogenic isolates tested.

The viable cells of the fourteen diarrheagenic*E. coli* were checked after NO treatment with primer pairs listed in [Table 1](#tab1){ref-type="table"} and PMA dye. The dye propidium monoazide (PMA Biotium Inc., Hayward, CA, USA) is a photoreactive dye with high affinity for DNA. The dye intercalates into DNA and forms a covalent linkage upon exposure to intense visible light. It is cell membrane impermeable. When a sample comprising both live and dead bacteria is treated with PMA, only dead cells are susceptible to DNA modification due to their compromised cell membranes \[[@B23], [@B24]\]. Therefore, selective detection of the sole live cells is achieved.

The fourteen ciprofloxacin resistant/less susceptible diarrheagenic*E. coli* seem to lose their virulence after NO treatment, because amplicons were obtained only with the primer pairs numbers 16 and 17 ([Table 1](#tab1){ref-type="table"}). This let us suppose that antibacterial activity acts on adhesion factor and membrane and its permeability with possible loss of extrachromosomal DNA.

4. Conclusions and Future Implications {#sec4}
======================================

Studies of new antimicrobials from plant derived extracts and agroindustrial byproducts as antimicrobials and preservatives are important issues in applied microbiology and biotechnology, for both implementing and improving effective alternative technologies to tackle antimicrobial resistance. The potential use of plant natural antimicrobials would require amendments of several different legal texts involving areas such as food additives, food packaging, and hygiene. Anyway, the applications could concern either the natural preservation in the food industries or an accessible and safe alternative to synthetic antimicrobial drugs.
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CVVI:

:   Central Vietnam Veterinary Institute

DAEC:

:   Diffusely adherent*E. coli*

DSMZ:

:   Leibniz-Institut DSMZ---Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

EAEC:

:   Enteroaggregative*E. coli*

EHEC:

:   Enterohemorrhagic*E. coli*

EIEC:

:   Enteroinvasive*E. coli*

ELISA:

:   Enzyme-linked immunosorbent assay

EPEC:

:   Enteropathogenic*E. coli*

ETEC:

:   Enterotoxigenic*E. coli*

GIZ:

:   Growth inhibition zone

HPTLC:

:   High performance thin layer chromatography

HUS:

:   Hemolytic uremic syndrome

LSD:

:   Least significant difference

NCE:

:   Neem cake extract

NL:

:   Department of Bacteriology and Animal Science, University of Wageningen, Netherlands

NO:

:   Neem oil

OD:

:   Optical density

PMA:

:   Propidium monoazide

RAPD PCR:

:   Random amplified polymorphic DNA polymerase chain reaction

Rf:

:   Ratio between the migration distance of substance and the migration distance of solvent front

SAS:

:   Statistical Analysis System (SAS Institute, Inc., Cary, NC, USA)

SD:

:   Standard deviation

TWN:

:   Tween 80

WTR:

:   Sterile distilled water.
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###### 

Primer pairs used to specifically amplify target gene coding for virulence factors (1--9 = toxins; 9--15 fimbriae) of *E. coli*and 16S rRNA (16-17).

  ----------------------------------------------------------------------------------------------------
  Target gene coding for virulence factors   Oligonucleotide sequences of primers         Reference
  ------------------------------------------ -------------------------------------------- ------------
  \(1\) LT                                   F 5′-ATT TAC GGC GTT ACT ATC CTC-3′ \        \[[@B25]\]
                                             R 5′-TTT TGG TCT CGG TCA GAT ATG-3′          

                                                                                          

  \(2\) Sta                                  F 5′-TCC GTG AAA CAA CAT GAC GG-3′ \         \[[@B26]\]
                                             R 5′-ATA ACA TCC AGC ACA GGC AG-3′           

                                                                                          

  \(3\) STb                                  F 5′-GCC TAT GCA TCT ACA CAA TC-3′ \         \[[@B26]\]
                                             R 5′-TGA GAA ATG GAC AAT GTC CG-3′           

                                                                                          

  \(4\) Stx1all                              F 5′-CGC TGA ATG TCA TTC GCT CTG C-3′ \      \[[@B27]\]
                                             R 5′-CGT GGT ATA GCT ACT GTC ACC-3′          

                                                                                          

  \(5\) Stx2all                              F 5′-CTT CGG TAT CCT ATT CCC GG-3′ \         \[[@B27]\]
                                             R 5′-CTG CTG TGA CAG TGA CAA AAC GC-3′       

                                                                                          

  \(6\) Stx2e                                F 5-ATG AAG AAG ATG TTT ATA GCG-3′ \         \[[@B25]\]
                                             R 5′-TCA GTT AAA CTT CAC CTG GGC-3′          

                                                                                          

  \(7\) EAST1                                F 5′-CCA TCA ACA CAG TAT ATC CGA-3′ \        \[[@B28]\]
                                             R 5′-GGT CGC GAG TGA CGG CTT TGT-3′          

                                                                                          

  \(8\) eae                                  F 5′-GGA ACG GCA GAG GTT AAT CTGCAG-3′ \     \[[@B27]\]
                                             R 5′-GGC GCT CAT CAT AGT CTTTC-3′            

                                                                                          

  \(9\) hlyA                                 F 5′-AGCTGCAAGTGCGGGTCTG-3′ \                \[[@B29]\]
                                             R 5′-TACGGGTTATGCCTGCAAGTTCAC-3′             

                                                                                          

  \(10\) F4 (K88)                            F 5′-GCT GCA TCT GCT GCA TCT GGTATG G-3′ \   \[[@B30]\]
                                             R 5′-CCA CTG AGT GCT GGTAGT TAC AGC C-3′     

                                                                                          

  \(11\) F5 (K99)                            F 5′-TGC GAC TAC CAA TGC TTC TG-3′ \         \[[@B26]\]
                                             R 5′-TAT CCA CCA TTA GAC GGA GC-3′           

                                                                                          

  \(12\) F6 (P987)                           F 5′-TCT GCT CTT AAA GCT ACT GG-3′ \         \[[@B25]\]
                                             R 5′-AAC TCC ACC GTT TGT ATC AG-3′           

                                                                                          

  \(13\) F17                                 F 5′-GGG CTG ACA GAG GAG GTG GGGC-3′ \       \[[@B30]\]
                                             R 5′-CCC GGC GAC AAC TTC ATCACC GG-3′        

                                                                                          

  \(14\) F18                                 F 5′-GTG AAA AGA CTA GTG TTT ATT TC-3′ \     \[[@B31]\]
                                             R 5′-CTT GTA AGT AAC CGC GTA AGC-3′          

                                                                                          

  \(15\) F41                                 F 5′-GAG GGA CTT TCA TCT TTT AG-3′ \         \[[@B26]\]
                                             R 5′-AGT CCA TTC CAT TTA TAG GC-3′           

                                                                                          

  \(16\) E16SI                               F 5′-CCCCCTGGACGAAGACTCAC-3′ \               \[[@B29]\]
                                             R 5′-ACCGCTGGCAACAAAGGATA -3′                

                                                                                          

  \(17\) E16SII                              F 5′-AGAGTTTGATGGCTCAG-3′ \                  \[[@B31]\]
                                             R 5′-GGACTACCAGGGTATCTAAT-3′                 
  ----------------------------------------------------------------------------------------------------

###### 

List of primer pairs\' amplification products, coordinates, and accession numbers.

  Target gene coding for virulence factors   Amplicon (bp)   Primer coordinates       Accession number
  ------------------------------------------ --------------- ------------------------ ------------------
  \(1\) LT                                   281             27--47, 287--307         S60731
  \(2\) STa                                  244             267--286, 492--510       M58746
  \(3\) STb                                  279             515--534, 773--793       AY028790
  \(4\) Stx1all                              302             113--134, 394--414       M17358
  \(5\) Stx2all                              516             50--69, 543--565         M59432
  \(6\) Stx2e                                264             1176--1196, 1419--1439   M36727
  \(7\) EAST1                                111             2--24, 94--114           S81691
  \(8\) eae                                  775             1441--1460, 2193--2215   AF022236
  \(9\) hylA                                 569             867-885, 1435--1412      X79839
  \(10\) F4 (K88)                            792             31--54, 798--822         M29374
  \(11\) F5 (K99)                            450             45--64, 475--494         M35282
  \(12\) F6 (P987)                           333             193--212, 506--525       M35257
  \(13\) F17                                 411             289--310, 677--699       AF055313
  \(14\) F18                                 510             1--23, 490--510          M61713
  \(15\) F41                                 431             154--173, 565--584       X14354
  \(16\) E16SI                               401             1628-170, 2063--2082     AB035924
  \(17\) E16SII                              798             8-27, 798--805           J01859

###### 

Molecular characterisation of enteropathogenic *E. coli* and reference strains considered in this study.

  *E. coli* isolate collection\'s designation   Surface antigen    Toxins           Fimbriae
  --------------------------------------------- ------------------ ---------------- ----------
  \(1\) CVVI K10B                               nd                 STb, LT, EAST1   F4
  \(2\) CVVI KH10                               nd                 STa, STb         F18
  \(3\) NLK99                                   O8K85K99           nr1              F5
  \(4\) NLP987                                  O64 : K; 9877      STa+             F6
  \(5\) CVVI E12b                               nd                 STa              F5, F41
  \(6\) CVVI E10                                nd                 STa              F5, F41
  \(7\) NLK99-1                                 O8 : K25 : K99     nr               F5
  \(8\) NLK99-3                                 O101 : K28 : K99   nr               F5
  \(9\) NLK99-5                                 O9 : K30 : K99     nr               F5
  \(10\) NLK99-7                                O101 : K32 : K99   nr               F5
  \(11\) NLK99-9                                O9 : K35 : K99     nr               F5
  \(12\) NLK99-11                               O9 : K37 : K99     nr               F5
  \(13\) NLK99-15                               O20 : K? : K99     nr               F5
  \(14\) NLK99-19                               O101 : K? : K99    nr               F5
  \(15\) DSMZ8696                               O55 : H6           nr               Nr
  \(16\) DSMZ9025                               ---                ---              ---
  \(17\) DSMZ10973                              O6                 nr               nr
  \(18\) ATCC33559                              ---                ---              ---

CVVI: Central Vietnam Veterinary Institute; NL: Department of Bacteriology and Animal Science, University of Wageningen, Netherlands; DSMZ: Leibniz-Institut DSMZ---Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; ATCC: American Type Culture Collection.

###### 

Antibacterial activity of neem oil (NO) against forty-eight *Escherichia coli* isolates revealed as growth inhibition zone (mm).

  *E. coli* isolates    Growth inhibition zone (mm)^\*^               
  --------------------- --------------------------------- ----- ----- -----------------
  \(1\) FLC 1056        11.33 ± 0.58 b                    ---   ---   30.41 ± 0.20 a
  \(2\) FLC 1247        16.13 ± 1.15 b                    ---   ---   30.52 ± 1.07 a
  \(3\) FLC 1059        15.83 ± 1.13 b                    ---   ---   29.62 ± 1.00 a
  \(4\) FLC 1243        19.00 ± 1.00 b                    ---   ---   31.53 ± 0.67 a
  \(5\) FLC 1048        12.33 ± 0.58 b                    ---   ---   29.42 ± 0.58 a
  \(6\) FLC 1167        9.50 ± 0.70 b                     ---   ---   30.61 ± 1.21 a
  \(7\) FLC 1249        13.33 ± 0.58 b                    ---   ---   29.61 ± 1.11 a
  \(8\) FLC 1055        14.53 ± 1.25 b                    ---   ---   31.75 ± 0.82 a
  \(9\) FLC 1054        16.23 ± 1.18 b                    ---   ---   31.41 ± 0.76 a
  \(10\) FLC 1085       18.00 ± 1.00 b                    ---   ---   30.53 ± 1.17 a
  \(11\) FLC 1244       15.33 ± 0.48 b                    ---   ---   28.86 ± 1.00 a
  \(12\) FLC 1165       19.50 ± 0.70 b                    ---   ---   31.33 ± 0.67 a
  \(13\) FLC 1086       11.33 ± 0.58 b                    ---   ---   29.82 ± 0.48 a
  \(14\) FLC 1053       14.53 ± 1.15 b                    ---   ---   32.65 ± 1.39 a
  \(15\) FLC 1095       16.83 ± 1.18 b                    ---   ---   29.05 ± 1.22 a
  \(16\) FLC 1219       10.70 ± 1.00 b                    ---   ---   32.75 ± 0.55 a
  \(17\) FLC 1235       13.23 ± 0.88 b                    ---   ---   30.15 ± 0.55 a
  \(18\) DSM8696        13.50 ± 0.50 b                    ---   ---   26.21 ± 1.00 a
  \(19\) DSM9025        13.33 ± 0.58 b                    ---   ---   21.64 ± 0.94 a
  \(20\) DSM10973       13.53 ± 1.25 b                    ---   ---   29.14 ± 1.75 a
  \(21\) ATCC33559      13.83 ± 1.18 b                    ---   ---   32.12 ± 1.09 a
  \(22\) CVVI E210      13.00 ± 1.00 a                    ---   ---   25.83 ± 1.65 a
  \(23\) CVVI E173      12.23 ± 0.58 b                    ---   ---   32.35 ± 1.49 a
  \(24\) CVVI E12b      27.50 ± 0.50 b                    ---   ---   11.25 ± 0.68 a
  \(25\) CVVI E16       14.33 ± 0.88 b                    ---   ---   27.54 ± 1.45 a
  \(26\) CVVI E320      21.53 ± 1.35 b                    ---   ---   28.75 ± 1.86 a
  \(27\) CVVI E130      11.83 ± 1.78 b                    ---   ---   29.64 ± 0.87 a
  \(28\) CVVI E48       10.00 ± 1.40 a                    ---   ---   29.31 ± 0.27 a
  \(29\) CVVI KH10      26.33 ± 0.53 b                    ---   ---   15.34 ± 0.66 a
  \(30\) CVVI K10B      27.50 ± 0.56 b                    ---   ---   0
  \(31\) CVVI E298      11.33 ± 0.48 b                    ---   ---   23.90 ± 1.69 a
  \(32\) CVVI E273      13.53 ± 1.75 b                    ---   ---   29.59 ± 1.77 b
  \(33\) CVVI K436      13.14 ± 1.68 b                    ---   ---   30.21 ± 1.38 a
  \(34\) CVVI E98       11.00 ± 1.00 a                    ---   ---   26.91 ± 1.56 a
  \(35\) CVVI E77       14.33 ± 0.58 b                    ---   ---   23.93 ± 0.59 a
  \(36\) CVVI E148      13.50 ± 0.50 b                    ---   ---   28.71 ± 0.87 a
  \(37\) CVVI E10       24.33 ± 0.58 b                    ---   ---   10.35 ± 1.11 a
  \(38\) CVVI E215      16.53 ± 1.15 b                    ---   ---   26.41 ± 1.40 a
  \(39\) NLK99/F5       29.83 ± 1.18 b                    ---   ---   16, 21 ± 0.89 a
  \(40\) NLP987/F5      30.00 ± 1.00 a                    ---   ---   13.21 ± 1.15 a
  \(41\) NLK99-1^\*^    21.73 ± 1.35 b                    ---   ---   15.34 ± 1.37 a
  \(42\) NLK99-3^\*^    28.33 ± 1.50 b                    ---   ---   0
  \(43\) NLK99-5^\*^    25.00 ± 1.10 a                    ---   ---   9.54 ± 1.11 a
  \(44\) NLK99-7^\*^    26.33 ± 0.58 b                    ---   ---   14,25 ± 1.11 a
  \(45\) NLK99-9^\*^    27.50 ± 0.50 b                    ---   ---   11.26 ± 1.78 a
  \(46\) NLK99-11^\*^   29.53 ± 1.25 b                    ---   ---   16.24 ± 1.68 a
  \(47\) NLK99-15^\*^   28.83 ± 1.38 b                    ---   ---   16.35 ± 1.11 a
  \(48\) NLK99-19^\*^   25.00 ± 1.70 a                    ---   ---   15.53 ± 0.84 a

Three paper discs per plate and three plates for each bacterium were considered. The experiment was repeated twice. Values are given as mean ± S.D. Values in a row followed by different lowercased letters are significantly different at *P* ≤ 0.05.

###### 

Bacterial growth reduction (%) at 24 h in liquid medium with different concentrations of NSO, using as reference the control treatment (without NSO).

  *E. coli* isolates    Percent growth reduction zone (%)                                       
  --------------------- ----------------------------------- ---------------- ------------------ ----------------
  \(1\) FLC 1056        39.25 ± 1.43 c                      35.61 ± 1.00 b   21.67 ± 1.33 a     11.31 ± 2.08 a
  \(2\) FLC 1247        25.51 ± 1.15 c                      24.70 ± 1.00 b   21.88 ± 1.33 a     11.86 ± 1.00 a
  \(3\) FLC 1059        31.51 ± 1.15 c                      25.70 ± 1.00 b   24.58 ± 1.33 a     14.86 ± 1.00 a
  \(4\) FLC 1243        38.90 ± 1.00 d                      28.79 ± 1.00 c   29.40 ± 0.00 b     16.68 ± 1.20 a
  \(5\) FLC 1048        25.60 ± 1.53 d                      23.73 ± 2.08 b   23.69 ± 2.00 b     12.83 ± 1.73 a
  \(6\) FLC 1167        23.71 ± 1.00 b                      21.61 ± 0.58 a   21.27 ± 0.00 a     11.18 ± 0.89 a
  \(7\) FLC 1249        29.65 ± 1.53 b                      28.61 ± 1.00 a   28.77 ± 1.33 a     18.51 ± 2.08 a
  \(8\) FLC 1055        34.51 ± 1.15 c                      29.70 ± 1.00 c   24.38 ± 1.33 a     14.86 ± 1.00 a
  \(9\) FLC 1054        31.51 ± 1.15 d                      29.70 ± 1.00 c   25\. 78 ± 1.33 a   14.86 ± 1.00 a
  \(10\) FLC 1085       39.90 ± 1.00 c                      28.79 ± 1.00 b   28.10 ± 0.00 b     15.58 ± 1.20 a
  \(11\) FLC 1244       35.70 ± 1.53 d                      28.73 ± 2.08 b   28.59 ± 2.00 b     12.63 ± 1.73 a
  \(12\) FLC 1165       39.71 ± 1.00 c                      29.61 ± 0.58 c   29.17 ± 0.00 b     16.48 ± 0.89 a
  \(13\) FLC 1086       39.55 ± 1.53 c                      28.61 ± 1.00 c   27.87 ± 1.33 b     12.21 ± 2.08 a
  \(14\) FLC 1053       34.51 ± 1.15 c                      89.70 ± 1.00 c   27.58 ± 1.33 b     14.86 ± 1.00 a
  \(15\) FLC 1095       31.51 ± 1.15 c                      29.70 ± 1.00 b   25.18 ± 1.33 a     14.86 ± 1.00 a
  \(16\) FLC 1219       38.95 ± 1.00 b                      28.79 ± 1.00 b   28.10 ± 0.00 b     16.68 ± 1.20 a
  \(17\) FLC 1235       36.70 ± 1.53 d                      27.73 ± 2.08 c   27.79 ± 2.00 b     12.83 ± 1.73 a
  \(18\) DSM8696        39.71 ± 1.00 c                      29.61 ± 0.58 c   29.67 ± 0.00 b     17.58 ± 0.89 a
  \(19\) DSM9025        39.65 ± 1.53 c                      28.61 ± 1.00 c   26.17 ± 1.33 b     18.10 ± 2.08 a
  \(20\) DSM10973       34.51 ± 1.15 c                      29.70 ± 1.00 c   23.28 ± 1.33 b     14.86 ± 1.00 a
  \(21\) ATCC33559      31.51 ± 1.15 d                      29.70 ± 1.00 c   21.58 ± 1.33 b     14.86 ± 1.00 a
  \(22\) CVVI E210      88.90 ± 1.00 c                      88.79 ± 1.00 c   69.20 ± 0.00 b     14.78 ± 1.20 a
  \(23\) CVVI E173      36.50 ± 1.53 d                      27.73 ± 2.08 c   27.99 ± 2.00 b     22.83 ± 1.73 a
  \(24\) CVVI E126      89.81 ± 1.00 c                      89.61 ± 0.58 c   69.37 ± 0.00 b     44.58 ± 0.89 a
  \(25\) CVVI E16       38.55 ± 1.53 c                      28.61 ± 1.00 c   27.57 ± 1.33 b     11.51 ± 2.08 a
  \(26\) CVVI E320      38.51 ± 1.15 c                      29.70 ± 1.00 c   27.18 ± 1.33 b     14.86 ± 1.00 a
  \(27\) CVVI E130      30.71 ± 1.15 c                      29.70 ± 1.00 c   27.68 ± 1.33 a     14.46 ± 1.00 a
  \(28\) CVVI E48       38.60 ± 1.00 c                      28.79 ± 1.00 c   29.20 ± 0.00 a     16.68 ± 1.20 a
  \(29\) CVVI KH10      99.60 ± 1.53 d                      81.73 ± 2.08 c   68.39 ± 2.00 b     62.33 ± 1.73 a
  \(30\) CVVI K10B      89.81 ± 1.00 c                      89.61 ± 0.58 c   69.37 ± 0.00 b     60.58 ± 0.89 a
  \(31\) CVVI E298      39.75 ± 1.53 c                      28.61 ± 1.00 c   27.57 ± 1.33 b     20.11 ± 2.08 a
  \(32\) CVVI E273      34.51 ± 1.15 c                      29.70 ± 1.00 c   26.58 ± 1.33 b     22.86 ± 1.00 a
  \(33\) CVVI K436      31.85 ± 1.15 d                      29.70 ± 1.00 c   27.18 ± 1.33 b     15.86 ± 1.00 a
  \(34\) CVVI E98       37.93 ± 1.00 c                      28.79 ± 1.00 c   29.50 ± 0.00 b     16.68 ± 1.20 a
  \(35\) CVVI E77       33.69 ± 1.53 d                      21.73 ± 2.08 c   27.29 ± 2.00 b     19.83 ± 1.73 a
  \(36\) CVVI E148      39.71 ± 1.00 c                      29.61 ± 0.58 c   29.57 ± 0.00 b     22.58 ± 0.89 a
  \(37\) CVVI E10       89.65 ± 1.53 c                      88.61 ± 1.00 c   61.67 ± 1.33 b     50.79 ± 2.08 a
  \(38\) CVVI E215      34.51 ± 1.15 c                      29.70 ± 1.00 c   17.58 ± 1.33 b     21.86 ± 1.00 a
  \(39\) NLK99/F5       91.51 ± 1.15 d                      89.70 ± 1.00 c   67.68 ± 1.33 b     61.86 ± 1.00 a
  \(40\) NL12B/F5       88.90 ± 1.00 c                      88.79 ± 1.00 c   69.60 ± 0.00 b     63.68 ± 1.20 a
  \(41\) NLK99-1^\*^    97.70 ± 1.53 d                      81.73 ± 2.08 c   68.69 ± 2.00 b     62.83 ± 1.73 a
  \(42\) NLK99-3^\*^    89.71 ± 1.00 c                      79.61 ± 0.58 c   69.57 ± 0.00 b     67.58 ± 0.89 a
  \(43\) NLK99-5^\*^    89.65 ± 1.53 c                      78.61 ± 1.00 c   67.67 ± 1.33 b     50.81 ± 2.08 a
  \(44\) NLK99-7^\*^    84.51 ± 1.15 c                      79.70 ± 1.00 c   67.58 ± 1.33 b     44.86 ± 1.00 a
  \(45\) NLK99-9^\*^    91.51 ± 1.15 c                      79.70 ± 1.00 c   67.28 ± 1.13 b     64.86 ± 1.00 a
  \(46\) NLK99-11^\*^   88.90 ± 1.00 c                      78.79 ± 1.00 c   69.60 ± 0.00 b     66.68 ± 1.20 a
  \(47\) NLK99-15^\*^   99.70 ± 1.53 d                      91.63 ± 0.28 c   68.69 ± 2.00 b     62.83 ± 1.73 a
  \(48\) NLK99-19^\*^   89.71 ± 1.00 c                      79.61 ± 0.58 c   69.57 ± 0.00 b     67.58 ± 0.89 a

Three plates for each bacterium were considered. The experiment was repeated twice. Values are given as mean ± S.D. Values in a row followed by different lowercased letters are significantly different at *P* ≤ 0.05.
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